Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40GTS | ISIN: CA8276471080 | Ticker-Symbol: QS0
Stuttgart
17.01.25
11:05 Uhr
4,480 Euro
-0,180
-3,86 %
Branche
Rohstoffe
Aktienmarkt
Sonstige
1-Jahres-Chart
SILVER CROWN ROYALTIES INC Chart 1 Jahr
5-Tage-Chart
SILVER CROWN ROYALTIES INC 5-Tage-Chart
ACCESS Newswire
757 Leser
Artikel bewerten:
(2)

PPX Mining Corp.: PPX Signs Definitive Agreement with Silver Crown Royalties

Finanznachrichten News

TORONTO, ON / ACCESSWIRE / December 16, 2024 / PPX Mining Corp. (TSXV:PPX.V)(BVL:PPX) (the "Company" or "PPX") is pleased to announce the signing of a definitive silver royalty agreement (the "Agreement") with Silver Crown Royalties Inc. (CBOE:SCRI)(OTCQX:SLCRF)(FRA:QS0) ("SCRi") last Friday December 13, 2024.

The Agreement contemplates the sale of a royalty (the "Royalty") for up to 15% of the cash equivalent of silver produced from PPX's Mina Callanquitas at its Igor 4 mining concession, located in La Libertad, Peru (the "Project"), less customary deductions, for aggregate proceeds of US$ 2,470,000.

The first tranche of US$ 1,000,000 is to be paid on closing ("Closing"), which is expected to occur in early 2025, with the second tranche of US$1,470,000 (the "Second Tranche") to be paid within six months of Closing. Upon Closing, SCRi will be granted a Royalty for 6% of the cash equivalent of silver produced from the Project, which will automatically be increased to 15% upon completion of the Second Tranche. If the Second Tranche is not completed within 6 months of Closing, PPX will have the right to repurchase the royalty for US$ 1,000,000, less any Royalty payments made to date. The Royalty will be payable immediately, based on current operations at the Project and will provide for minimum deliveries of the cash equivalent of 14,062.5 ounces of silver per quarter up to a total of 225,000 ounces. Minimum deliveries will be applicable the earlier of: a) October 1, 2025; and b) the startup of metallurgical operations at the beneficiation plant, currently under construction. Upon the delivery of the cash equivalent of 225,000 ounces of silver to SCRi, the silver royalty will automatically terminate.

John Thomas, CEO commented, "We welcome SCRi's funding. It will support construction activities at site, as well as other working capital requirements during this critical and transformational period for the Company."

About Silver Crown Royalties Inc.

Founded by industry veterans, SCRi is a publicly traded, silver royalty company. SCRi currently has four silver royalties of which three are revenue-generating. Its business model presents investors with precious metals exposure allowing for a natural hedge against currency devaluation while minimizing the negative impact of cost inflation associated with production. SCRi endeavors to minimize the economic impact on mining projects while maximizing returns for shareholders.

About PPX Mining Corp:

PPX Mining Corp. is a Canadian-based mining company with assets in northern Peru. Igor, the Company's 100%-owned flagship gold and silver project, is located in the prolific Northern Peru gold belt in eastern La Libertad Department.

On behalf of the Board of Directors

John Thomas
Chief Executive Officer

82 Richmond Street East
Toronto, Ontario M5C 1P1
Canada
416-361-0737

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement:

This press release contains forward-looking information and forward-looking statements (collectively, "forward-looking statements") as such terms are defined by applicable securities laws, including, but not limited to statements regarding test results, future plans or management estimates. Forward-looking statements are statements that relate to future events. In this context, forward-looking statements often address expected future business plans and financial performance and often contain words such as "anticipate," "believe," "plan," "estimate," "expect," and "intend,", statements that an action or event "may," "might," "could," "should," "would" or "will" be taken or occur, or other similar expressions. Forward-looking statements are subject to a number of known and unknown risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control, and the Company's actual results could differ materially from those stated or implied in forward-looking statements due to many various factors. Such uncertainties and risks include, among others, delays in obtaining or inability to obtain any required regulatory approvals, if applicable. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur. The timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, one should not place undue reliance on forward- looking statements. All forward-looking statements contained in this press release are made as of today's date, and the Company undertakes no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

SOURCE: PPX Mining Corp.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.